Vitamin D, light and mental health

Journal of Photochemistry and Photobiology B: Biology

Volumn 101, Issue 2, 2010, Pages 142-149

  Humble, Mats B ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autism; Depressive disorders; Neurotrophic factors; Phototherapy; Schizophrenia; Vitamin D

Indexed keywords

CALCITRIOL; MELATONIN; NEUROTRANSMITTER; NEUROTROPHIC FACTOR; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; AUTISM; CENTRAL NERVOUS SYSTEM; DEPRESSION; ENVIRONMENTAL FACTOR; HUMAN; MENTAL HEALTH; NUTRITIONAL STATUS; PATHOGENESIS; PHOTOTHERAPY; PINEAL BODY; PRENATAL PERIOD; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEASONAL VARIATION; VITAMIN D DEFICIENCY;

AUTISTIC DISORDER; DEPRESSIVE DISORDER; HUMANS; LIGHT; MENTAL DISORDERS; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77956553770     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2010.08.003     Document Type: Article

References (133)

1. Gibbs D. Rickets and the crippled child: an historical perspective. J. Roy. Soc. Med. 1994, 87:729-732.
2. Rajakumar K., Greenspan S.L., Thomas S.B., Holick M.F. Solar ultraviolet radiation and vitamin D: a historical perspective. Am. J. Public Health 2007, 97:1746-1754.
3. Jacobi A. Nervous symptoms in rhachitis, Arch. Pediatr. 13 (1896) 801-806, quoted in: M.T. Weick, A history of rickets in the United States. Am. J. Clin. Nutr. 1967, 20:1234-1241.
4. Ness A.R., Frankel S.J., Gunnell D.J., Smith G.D. Are we really dying for a tan?. BMJ 1999, 319:114-116.
5. Cross-National Collaborative Group, The changing rate of major depression. Cross-national comparisons, JAMA 268 (1992) 3098-3105.
6. Fombonne E. Increased rates of psychosocial disorders in youth. Eur. Arch. Psychiatry Clin. Neurosci. 1998, 248:14-21.
7. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC), Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006, M. M. W. R. Surveill. Summ. 58 (2009) 1-20.
8. Stumpf W.E., Sar M., Clark S.A., DeLuca H.F. Brain target sites for 1,25-dihydroxyvitamin D3. Science 1982, 215:1403-1405.
9. Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 2005, 29:21-30.
10. Garcion E., Wion-Barbot N., Montero-Menei C.N., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol. Metab. 2002, 13:100-105.
11. Kiraly S.J., Kiraly M.A., Hawe R.D., Makhani N. Vitamin D as a neuroactive substance: review. Scientific World J. 2006, 6:125-139.
12. Kalueff A.V., Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:12-19.
13. Puchacz E., Stumpf W.E., Stachowiak E.K., Stachowiak M.K. Vitamin D increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Brain Res. Mol. Brain Res. 1996, 36:193-196.
14. Sonnenberg J., Luine V.N., Krey L.C., Christakos S. 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986, 118:3-1439.
15. Stio M., Lunghi B., Celli A., Treves C. Vitamin D-related modification of enzyme activities in synaptosomes and mitochondria isolated from rat cerebral cortex. Biochem. Mol. Biol. Int. 1995, 37:813-820.
16. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
17. Humble M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr. Scand. Suppl. 2000, 402:28-36.
18. Drevets W.C., Furey M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized. Placebo-controlled clinical trial. Biol. Psychiatry 2010, 67:432-438.
19. Wion D., MacGrogan D., Neveu I., Jehan F., Houlgatte R., Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J. Neurosci. Res. 1991, 28:110-114.
20. Brown J., Bianco J.I., McGrath J.J., Eyles D.W. 1,25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci. Lett. 2003, 343:139-143.
21. Naveilhan P., Neveu I., Wion D., Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. NeuroReport 1996, 7:2171-2175.
22. Neveu I., Naveilhan P., Baudet C., Brachet P., Metsis M. 1,25-Dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. NeuroReport 1994, 6:124-126.
23. Cattaneo A., Capsoni S., Paoletti F. Towards non invasive nerve growth factor therapies for Alzheimer's disease. J. Alzheimers Dis. 2008, 15:255-283.
24. Angelucci F., Aloe L., Jiménez-Vasquez P., Mathé A.A. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int. J. Neuropsychopharmacol. 2003, 6:225-231.
25. Pae C.U., Marks D.M., Han C., Patkar A.A., Steffens D. Does neurotropin-3 have a therapeutic implication in major depression?. Int. J. Neurosci. 2008, 118:1515-1522.
26. Shoval G., Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur. Neuropsychopharmacol. 2005, 15:319-329.
27. Zhang X., Zhang Z., Xie C., Xi G., Zhou H., Zhang Y., Sha W. Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:886-890.
28. Zhang X., Zhang Z., Sha W., Xie C., Xi G., Zhou H., Zhang Y. Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drug-resistant depression. Psychiatry Res. 2009, 170:273-275.
29. Hong M., Mukhida K., Mendez I. GDNF therapy for Parkinson's disease. Expert Rev. Neurother. 2008, 8:1125-1139.
30. Carnicella S., Ron D. GDNF - a potential target to treat addiction. Pharmacol. Ther. 2009, 122:9-18.
31. Garcion E., Sindji L., Leblondel G., Brachet P., Darcy F. 1,25-Dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J. Neurochem. 1999, 73:859-866.
32. Cass W.A., Smith M.P., Peters L.E. Calcitriol protects against the dopamine- and serotonin-depleting effects of neurotoxic doses of methamphetamine. Ann. NY Acad. Sci. 2006, 1074:261-271.
33. Sanchez B., Relova J.L., Gallego R., Ben-Batalla I., Perez-Fernandez R. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J. Neurosci. Res. 2009, 87:723-732.
34. Ibi M., Sawada H., Nakanishi M., Kume T., Katsuki H., Kaneko S., Shimohama S., Akaike A. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001, 40:761-771.
35. Taniura H., Ito M., Sanada N., Kuramoto N., Ohno Y., Nakamichi N., Yoneda Y. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J. Neurosci. Res. 2006, 83:1179-1189.
36. E. Esquirol, Des Maladies Mentales, J.-B. Baillière, Paris, 1838, pp. 465-467.
37. Rosenthal N.E., Sack D.A., Gillin J.C., Lewy A.J., Goodwin F.K., Davenport Y., Mueller P.S., Newsome D.A., Wehr T.A. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatry 1984, 41:72-80.
38. Golden R.N., Gaynes B.N., Ekstrom R.D., Hamer R.M., Jacobsen F.M., Suppes T., Wisner K.L., Nemeroff C.B. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am. J. Psychiatry 2005, 162:656-662.
39. Westrin Å., Lam R.W. Seasonal affective disorder: a clinical update. Ann. Clin. Psychiatry 2007, 19:239-246.
40. The Swedish Council on Technology Assessment in Health Care, Light therapy for depression and other treatment of seasonal affective disorder, a systematic review, Report No: 186, SBU, Stockholm, 2007.
41. Lam R.W., Levitan R.D. Pathophysiology of seasonal affective disorder: a review. J. Psychiatry Neurosci. 2000, 25:469-480.
42. Koorengevel K.M., Beersma D.G., den Boer J.A., van den Hoofdakker R.H. Mood regulation in seasonal affective disorder patients and healthy controls studied in forced desynchrony. Psychiatry Res. 2003, 117:57-74.
43. Rüger M., Gordijn M.C., Beersma D.G., de Vries B., Daan S. Weak relationships between suppression of melatonin and suppression of sleepiness/fatigue in response to light exposure. J. Sleep Res. 2005, 14:221-227.
44. Wileman S.M., M Eagles J., Andrew J.E., Howie F.L., Cameron I.M., McCormack K., Naji S.A. Light therapy for seasonal affective disorder in primary care: randomised controlled trial. Br. J. Psychiatry 2001, 178:311-316.
45. Meesters Y., Beersma D.G., Bouhuys A.L., van den Hoofdakker R.H. Prophylactic treatment of seasonal affective disorder (SAD) by using light visors: bright white or infrared light?. Biol. Psychiatry 1999, 46:239-246.
46. Wehr T.A., Skwerer R.G., Jacobsen F.M., Sack D.A., Rosenthal N.E. Eye versus skin phototherapy of seasonal affective disorder. Am. J. Psychiatry 1987, 144:753-757.
47. Eastman C.I., Martin S.K., Hebert M. Failure of extraocular light to facilitate circadian rhythm reentrainment in humans. Chronobiol. Int. 2000, 17:807-826.
48. Koorengevel K.M., Gordijn M.C., Beersma D.G., Meesters Y., den Boer J.A., van den Hoofdakker R.H., Daan S. Extraocular light therapy in winter depression: a double-blind placebo-controlled study. Biol. Psychiatry 2001, 50:691-698. (Erratum in: Biol. Psychiatry 51 (2002) 194).
49. Sancar A. Regulation of the mammalian circadian clock by cryptochrome. J. Biol. Chem. 2004, 279:34079-34082.
50. Pjrek E., Winkler D., Stastny J., Konstantinidis A., Heiden A., Kasper S. Bright light therapy in seasonal affective disorder - does it suffice?. Eur. Neuropsychopharmacol. 2004, 14:347-351.
51. San L., Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry 2008, 23:396-402.
52. Monteleone P., Maj M. The circadian basis of mood disorders: recent developments and treatment implications. Eur. Neuropsychopharmacol. 2008, 18:701-711.
53. Pjrek E., Winkler D., Konstantinidis A., Willeit M., Praschak-Rieder N., Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl.) 2007, 190:575-579.
54. Lee T.M., Chan C.C., Paterson J.G., Janzen H.L., Blashko C.A. Spectral properties of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr. Scand. 1997, 96:117-121.
55. Oren D.A., Schulkin J., Rosenthal N.E. 1,25 (OH)2 vitamin D3 levels in seasonal affective disorder: effects of light. Psychopharmacology (Berl.) 1994, 116:515-516.
56. Partonen T., Vakkuri O., Lamberg-Allardt C., Lönnqvist J. Effects of bright light on sleepiness, melatonin, and 25-hydroxyvitamin D(3) in winter seasonal affective disorder. Biol. Psychiatry 1996, 39:865-872.
57. J.P. Docherty, H.M. Hafez, A.F. Frank, B.A. Welch, Wavelength study of phototherapy for seasonal affective disorder, in: Proceedings of the 141st Annual Meeting of the American Psychiatric Association, Montreal, 1988, p. 143 (Abstract).
58. Lam R.W., Buchanan A., Clark C.M., Remick R.A. Ultraviolet versus non-ultraviolet light therapy for seasonal affective disorder. J. Clin. Psychiatry 1991, 52:213-216.
59. Lam R.W., Buchanan A., Mador J.A., Corral M.R., Remick R.A. The effects of ultraviolet - a wavelengths in light therapy for seasonal depression. J. Affect. Disord. 1992, 24:237-243.
60. Stumpf W.E., Privette T.H. Light, vitamin D and psychiatry. Role of 1,25 dihydroxyvitamin D3 (soltriol) in etiology and therapy of seasonal affective disorder and other mental processes. Psychopharmacology (Berl.) 1989, 97:285-294.
61. Lansdowne A.T., Provost S.C. Vitamin D3 enhances mood in healthy subjects during winter. Psychopharmacology (Berl.) 1998, 135:319-323.
62. Gloth F.M., Alam W., Hollis B. Vitamin D vs. broad spectrum phototherapy in the treatment of seasonal affective disorder. J. Nutr. Health Aging 1999, 3:5-7.
63. Shipowick C.D., Moore C.B., Corbett C., Bindler R. Vitamin D and depressive symptoms in women during the winter: a pilot study. Appl. Nurs. Res. 2009, 22:221-225.
64. Harris S., Dawson-Hughes B. Seasonal mood changes in 250 normal women. Psychiatry Res. 1993, 49:77-87.
65. Dumville J.C., Miles J.N., Porthouse J., Cockayne S., Saxon L., King C. Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. J. Nutr. Health Aging 2006, 10:151-153.
66. Jorde R., Waterloo K., Saleh F., Haug E., Svartberg J. Neuropsychological function in relation to serum parathyroid hormone and serum 25-hydroxyvitamin D levels. The Tromsø study. J. Neurol. 2006, 253:464-470.
67. Hoogendijk W.J., Lips P., Dik M.G., Deeg D.J., Beekman A.T., Penninx B.W. Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch. Gen. Psychiatry 2008, 65:508-512.
68. Pan A., Lu L., Franco O.H., Yu Z., Li H., Lin X. Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese. J. Affect. Disord. 2009, 118:240-243.
69. Schneider B., Weber B., Frensch A., Stein J., Fritz J. Vitamin D in schizophrenia, major depression and alcoholism. J. Neural Transm. 2000, 107:839-842.
70. Berk M., Sanders K.M., Pasco J.A., Jacka F.N., Williams L.J., Hayles A.L., Dodd S. Vitamin D deficiency may play a role in depression. Med. Hypotheses 2007, 69:1316-1319.
71. Berk M., Jacka F.N., Williams L.J., Ng F., Dodd S., Pasco J.A. Is this D vitamin to worry about? Vitamin D insufficiency in an inpatient sample. Aust. NZ J. Psychiatry 2008, 42:874-878.
72. Humble M.B., Gustafsson S., Bejerot S. Low serum levels of 25-hydroxyvitamin D (25-OHD) among psychiatric out-patients in Sweden: relations with season, age, ethnic origin and psychiatric diagnosis. J. Steroid Biochem. Mol. Biol. 2010, 121:467-470.
73. Vieth R., Kimball S., Hu A., Walfish P.G. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100mcg (4000IU) per day on biochemical responses and the wellbeing of patients. Nutr. J. 2004, 3:8.
74. Jorde R., Sneve M., Figenschau Y., Svartberg J., Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J. Int. Med. 2008, 264:599-609.
75. Bertone-Johnson E.R. Vitamin D and the occurrence of depression: causal association or circumstantial evidence?. Nutr. Rev. 2009, 67:481-492.
76. Murphy P.K., Wagner C.L. Vitamin D and mood disorders among women: an integrative review. J. Midwifery Womens Health 2008, 53:440-446.
77. Young S.N. Has the time come for clinical trials on the antidepressant effect of vitamin D?. J. Psychiatry Neurosci. 2009, 34:3.
78. Hyppönen E., Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr. 2007, 85:860-868.
79. Tremlett H., van der Mei I.A., Pittas F., Blizzard L., Paley G., Mesaros D., Woodbaker R., Nunez M., Dwyer T., Taylor B.V., Ponsonby A.L. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271-279.
80. Carlsson A., Svennerholm L., Winblad B. Seasonal and circadian monoamine variations in human brains examined post mortem. Acta Psychiatr. Scand. Suppl. 1980, 280:75-85.
81. Malmgren R., Åberg-Wistedt A., Mårtensson B. Aberrant seasonal variations of platelet serotonin uptake in endogenous depression. Biol. Psychiatry 1989, 25:393-402.
82. Spigset O., Allard P., Mjörndal T. Circannual variations in the binding of [3H] lysergic acid diethylamide to serotonin2A receptors and of [3H] paroxetine to serotonin uptake sites in platelets from healthy volunteers. Biol. Psychiatry 1998, 43:774-780.
83. Praschak-Rieder N., Willeit M., Wilson A.A., Houle S., Meyer J.H. Seasonal variation in human brain serotonin transporter binding. Arch. Gen. Psychiatry 2008, 65:1072-1078.
84. Kalbitzer J., Erritzoe D., Holst K.K., Nielsen F.A., Marner L., Lehel S., Arentzen T., Jernigan T.L., Knudsen G.M. Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol. Psychiatry 2010, 67:1033-1039.
85. Stain-Malmgren R., Kjellman B.F., Åberg-Wistedt A. Platelet serotonergic functions and light therapy in seasonal affective disorder. Psychiatry Res. 1998, 78:163-172.
86. Neumeister A., Turner E.H., Matthews J.R., Postolache T.T., Barnett R.L., Rauh M., Vetticad R.G., Kasper S., Rosenthal N.E. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch. Gen. Psychiatry 1998, 55:524-530.
87. Pjrek E., Konstantinidis A., Assem-Hilger E., Praschak-Rieder N., Willeit M., Kasper S., Winkler D. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. J. Psychiatr. Res. 2009, 43:792-797.
88. Eriksson E., Humble M.B. Serotonin in psychiatric pathophysiology: a review of data from experimental and clinical research. Progress in Basic and Clinical Pharmacology 1990, vol. 3:66-119. Karger, Basel. R. Pohl, S. Gershon (Eds.).
89. Ozkan S., Jindal S., Greenseid K., Shu J., Zeitlian G., Hickmon C., Pal L. Replete vitamin D stores predict reproductive success following in vitro fertilization. Fertil. Steril. 2009, 34:87. 10.1016/j.fertnstert.2009.05.019.
90. Wehr E., Pilz S., Boehm B.O., März W., Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin. Endocrinol. (Oxf.) 2010, 73:243-248.
91. Rosen L.N., Targum S.D., Terman M., Bryant M.J., Hoffman H., Kasper S.F., Hamovit J.R., Docherty J.P., Welch B., Rosenthal N.E. Prevalence of seasonal affective disorder at four latitudes. Psychiatry Res. 1990, 31:131-144.
92. Mersch P.P., Middendorp H.M., Bouhuys A.L., Beersma D.G., van den Hoofdakker R.H. Seasonal affective disorder and latitude: a review of the literature. J. Affect. Disord. 1999, 53:35-48.
93. Axelsson J., Stefánsson J.G., Magnússon A., Sigvaldason H., Karlsson M.M. Seasonal affective disorders: relevance of Icelandic and Icelandic-Canadian evidence to etiologic hypotheses. Can. J. Psychiatry 2002, 47:153-158.
94. Axelsson J., Ragnarsdóttir S., Pind J., Sigbjörnsson R. Chromaticity of daylight: is the spectral composition of daylight an aetiological element in winter depression?. Int. J. Circumpolar Health 2004, 63:145-156.
95. Insel T.R., Wang P.S. The STAR*D trial: revealing the need for better treatments. Psychiatry Serv. 2009, 60:1466-1467.
96. Hillhouse J., Stapleton J., Turrisi R. Association of frequent indoor UV tanning with seasonal affective disorder. Arch. Dermatol. 2005, 141:1465.
97. Feldman S.R., Liguori A., Kucenic M., Rapp S.R., Fleischer A.B., Lang W., Kaur M. Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. J. Am. Acad. Dermatol. 2004, 51:45-51.
98. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 2000, 57:637-648.
99. Pardo C.A., Eberhart C.G. The neurobiology of autism. Brain Pathol. 2007, 17:434-447.
100. Eyles D., Brown J., Mackay-Sim A., McGrath J., Féron F. Vitamin D3 and brain development. Neuroscience 2003, 118:641-653.
101. Fernandes de Abreu D.A., Eyles D., Féron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 2009, 34(Suppl. 1):S265-277.
102. Eyles D.W., Feron F., Cui X., Kesby J.P., Harms L.H., Ko P., McGrath J.J., Burne T.H. Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 2009, 34(Suppl. 1):S247-S257.
103. Féron F., Burne T.H., Brown J., Smith E., McGrath J.J., Mackay-Sim A., Eyles D.W. Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res. Bull. 2005, 65:141-148.
104. Kalueff A.V., Tuohimaa P P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr. Opin. Clin. Nutr. Metab. Care 2007, 10:12-19.
105. Susser E., Neugebauer R., Hoek H.W., Brown A.S., Lin S., Labovitz D., Gorman J.M. Schizophrenia after prenatal famine. Further evidence. Arch. Gen. Psychiatry 1996, 53:25-31.
106. Brown A.S., Susser E.S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr. Bull. 2008, 34:1054-1063.
107. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia?. Schizophr. Res. 1999, 40:173-177.
108. Mackay-Sim A., Féron F., Eyles D., Burne T., McGrath J. Schizophrenia, vitamin D, and brain development. Int. Rev. Neurobiol. 2004, 59:351-380.
109. Kinney D.K., Teixeira P., Hsu D., Napoleon S.C., Crowley D.J., Miller A., Hyman W., Huang E. Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin D deficiency and infections?. Schizophr. Bull. 2009, 35:582-595.
110. Davies G., Welham J., Chant D.C., Torrey E.F., McGrath J. Season of birth effect and latitude: a systematic review and meta-analyses of northern hemisphere studies. Schizophr. Bull. 2003, 29:587-593.
111. Saha S., Chant D.C., Welham J.L., McGrath J.J. The incidence and prevalence of schizophrenia varies with latitude. Acta Psychiatr. Scand. 2006, 114:36-39.
112. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Järvelin M.R., Chant D., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 2004, 67:237-245.
113. Pedersen C.B., Mortensen PB P.B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch. Gen. Psychiatry 2001, 58:1039-1046.
114. McGrath J.J., Kimlin M.G., Saha S., Eyles D.W., Parisi A.V. Vitamin D insufficiency in south-east Queensland. Med. J. Aust. 2001, 174:150-151.
115. Cantor-Graae E., Zolkowska K., McNeil T.F. Increased risk of psychotic disorder among immigrants in Malmö: a 3-year first-contact study. Psychol. Med. 2005, 35:1155-1163.
116. Dealberto M.J. Why are immigrants at increased risk for psychosis? Vitamin D insufficiency, epigenetic mechanisms, or both?. Med. Hypotheses 2007, 68:259-267.
117. Cantor-Graae E., Selten J.P. Schizophrenia and migration: a meta-analysis and review. Am. J. Psychiatry 2005, 162:12-24.
118. Dealberto M.J. Ethnic origin and increased risk for schizophrenia in immigrants to countries of recent and longstanding immigration. Acta Psychiatr. Scand. 2010, 121:325-339.
119. Fleischhacker W.W., Cetkovich-Bakmas M., De Hert M., Hennekens C.H., Lambert M., Leucht S., Maj M., McIntyre R.S., Naber D., Newcomer J.W., Olfson M., Ösby U., Sartorius N., Lieberman J.A. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J. Clin. Psychiatry 2008, 69:514-519.
120. Melkersson K.I., Dahl M.L., Hulting A.L. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism. Psychopharmacology (Berl.) 2004, 175:1-6.
121. Boucher B.J. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome 'X'?. Br. J. Nutr. 1998, 79:315-327. (Erratum in: Br. J. Nutr. 80 (1998) 585).
122. Reis J.P., von Mühlen D., Miller E.R. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur. J. Endocrinol. 2008, 159:41-48.
123. Krakowski M., Czobor P., Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr. Res. 2009, 110:95-102.
124. Cannell J.J. Autism and vitamin D. Med. Hypotheses 2008, 70:750-759.
125. Waldman M., Nicholson S., Adilov N., Williams J. Autism prevalence and precipitation rates in California, Oregon, and Washington counties. Arch. Pediatr. Adolesc. Med. 2008, 162:1026-1034.
126. Kinney D.K., Barch D.H., Chayka B., Napoleon S., Munir K.M. Environmental risk factors for autism: do they help cause de novo genetic mutations that contribute to the disorder?. Med. Hypotheses 2010, 74:102-106.
127. Barnevik-Olsson M., Gillberg C., Fernell E. Prevalence of autism in children born to Somali parents living in Sweden: a brief report. Dev. Med. Child Neurol. 2008, 50:598-601.
128. Keen D.V., Reid F.D., Arnone D. Autism, ethnicity and maternal immigration. Br. J. Psychiatry 2010, 196:274-281.
129. Fernell E., Barnevik-Olsson M., Bågenholm G., Gillberg C., Gustafsson S., Sääf M. Serum levels of 25-hydroxyvitamin D in mothers of Swedish and of Somali origin who have children with and without autism. Acta Paediatr. 2010, 99:743-747.
130. Saag K. Mend the mind, but mind the bones!: balancing benefits and potential skeletal risks of serotonin reuptake inhibitors. Arch. Int. Med. 2007, 167:1231-1232.
131. Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J. Clin. Psychopharmacol. 2008, 28:411-417.
132. Meaney A.M., O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr. Res. 2007, 93:136-143.
133. Kishimoto T., Watanabe K., Shimada N., Makita K., Yagi G., Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry 2008, 69:385-391.